Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Vidhya Karivedu
Medical Assistant Professor in the Department of Medicine
Medicine, Medical Oncology
vidhya.karivedu@duke.edu
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
Professional Training and Employment
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMABAND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA
Clinical Trial
Principal Investigator ·
Awarded by Regeneron Pharmaceuticals, Inc. ·
2025 - 2030
Phase 3 open-label, randomized, controlled study to evaluate the efficacy & safety of petosemtamab compared with investigators choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell
Clinical Trial
Principal Investigator ·
Awarded by Merus N.V. ·
2025 - 2030
A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Clinical Trial
Principal Investigator ·
Awarded by Merus N.V. ·
2025 - 2030
